Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.
Financial Statements
- Click here to download Incyte Corp.'s Income Statement
- Click here to download Incyte Corp.'s Balance Sheet
- Click here to download Incyte Corp.'s Statement of Cash Flows
Key Info
- Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Sector: Professional, Scientific, and Technical Services
- CEO Name: Paul Friedman
Key Statistics
- Stock Price: $68.78
- Dividend Yield: 0%
- Market Capitalization: $15,164,757,922
- Shares Outstanding: 220,835,269
- Number of Employees: 1,773
- Trailing 12-Month EPS: $1.54
- Trailing 12-Month DPS: $0
- Payout Ratio: 0.0%
Important Dates
- Next Earnings Date: 2021-11-02
- Next Ex-Dividend Date:
Price Trends
- Current Stock Price: $68.78
- 52-week high: $101.47
- 52-week low: $67.87
- 200-day moving average: $79.79
- 50-day moving average: $73.8
Performance
- 1-Month Price Return: -9.3%
- 3-Month Price Return: -18.9%
- 6-Month Price Return: -15.3%
- 1-Year Price Return: -21.5%
- 2-Year Price Return: -5.7%
- 5-Year Price Return: -25.6%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast